Navigation Links
Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells

NEW YORK--(BUSINESS WIRE)--Apr 16, 2007 - Arsenic, a naturally occurring element, has been used in therapeutic compounds for over 2,000 years, and even now remains a venerable constituent of the traditional Chinese pharmacopeia.

Today, due in measure to the efforts of investigators supported by grants from the Samuel Waxman Cancer Research Foundation's (SWCRF) "Institute Without Walls," an arsenic derivative is being utilized in therapy for the treatment of certain types of acute leukemia.

In an important new development that holds promise for wider use of arsenic for treatment of other forms of cancer, the January 3, 2007 issue of the Journal of the National Cancer Institute published the results of research describing a new mode of action of arsenite (a form of the metal arsenic) in the treatment of acute promyelocytic leukemia (APL).

The research, conducted by Dr. Ethan Dmitrovsky, and his colleagues at Dartmouth Medical School, determined that arsenite selectively destroys APL cells. It was observed that arsenite causes a form of cell "suicide" in which digestive enzymes usually sequestered within the cancer cell are released into the cell at large.

Dr. Samuel Waxman, Founder and Scientific Director of SWCRF, notes "This discovery of a new mode of action of arsenic-based therapies establishes a new pathway that can lead to broader use of arsenic in developing therapies for treating other forms of cancer. It most certainly presents a new platform of knowledge that can stimulate new ideas that may ultimately increase the cure rate of APL to near 100%."

SWCRF provided grants supporting the research program led by Dr. Dmitrovsky, who is the Andrew G. Wallace Professor of Medicine and Pharmacology and Chairman, Pharmacology and Toxicology of Dartmouth Medical School, and also serves as Associate Scientific Director of SWCRF.

Arsenic and its derivatives are now part of the stand ard treatment for APL. Recent information indicates that the combination of the vitamin A derivative retinoic acid, arsenic and chemotherapy may cure over 90% of APL patients, which may result in extending the lives of an estimated 50,000 people a year.

About SWCRF

Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy. Two drugs developed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL).

Since its inception, SWCRF has trained and supported more than 170 scientists with research grants exceeding $60 million. Based in New York City at The Mount Sinai Medical Center, the Foundation funds highly collaborative basic, translational and clinical research groups throughout the United States, Canada, China, Europe and Israel. SWCRF grant applicants are established investigators who agree to collaborate with other SWCRF investigators on all research projects funded by the Foundation.

Functioning as an "Institute Without Walls" the Foundation currently enables the collaboration of accomplished scientists in 28 different world-renown cancer research centers around the world. SWCRF hosts international conferences that bring together differentiation therapy investigators in a major forum to share their findings with the scientific community. Foundation-supported projects are reviewed and evaluated annually by an independent external committee of eminent scientists.

The Foundation derives most of its support from individual contributions. For the third consecutive year, Charity Navigator has awarded SWCRF its coveted four-star rating, indicating that the Foundation operates in the most fiscal ly responsible way possible to utilize its resources to attain its goal of a world without cancer.

For more information, visit www.waxmancancer.org.

Contact

Broadford & Maloney Inc.
Martin Maloney, 203-661-2900
m.maloney@bmcorp.com
or
Samuel Waxman Cancer Research Institute
Merle Duskin Kailas, 212-241-1760
mkailas@waxmancancer.org


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... and infrastructure. Most providers, however, are unsure how to move forward, given the ... to define a path forward tailored to an organization’s specific needs. , PYA ...
(Date:6/24/2016)... ... ... SpiritQuest Sedona Retreats, located in Arizona has re-located to 75 Kallof Place, ... Rock, Airport Mesa, and Boynton Canyon. The new retreat center is ideally-situated ... the Sedona Rouge, both popular accommodations for SpiritQuest clients. The Medicine Wheel, Labyrinth ...
(Date:6/23/2016)... ... 2016 , ... An article published June 8 on AOL News ... neck cancer in individuals with unhealthy oral hygiene habits. The article goes on to ... had gum disease, brushed their teeth on a daily basis, wore dentures and if ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. ... mobile security software, is featured in the current issue of Silicon Review ... companies with innovative technology solutions and features them in their magazine. The magazine ...
Breaking Medicine News(10 mins):